Listed

Abpro Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2026

Filed with the SEC on Aug 14, 2026 and accepted by EDGAR at Aug 14, 2026, 16:06 ET.

Share

Management's discussion and analysis

As filed, 24,298 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q (“Quarterly Report”) and with our audited financial statements and the notes thereto included in our Annual Report. In addition, you should read the “Risk Factors” and “Information Regarding Forward-Looking Statements” sections of this Quarterly Report and our Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Unless otherwise indicated or the context otherwise requires, references in this section to “Abpro,” “we,” “us,” “our,” “the Company,” and other similar terms refer to Abpro Holdings, Inc. and its subsidiaries.

Overview

Abpro Holdings, Inc. (together with its subsidiaries, the “Company”) is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. The Company is focused on the development of novel antibodies using its proprietary discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology and infectious disease. By leveraging our proprietary DiversImmune® and MultiMabTM antibody discovery and engineering platforms, we are developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions.

Our two lead product candidates, ABP-102 and ABP-201, feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2, or HER2, and cluster of differentiation 3, or CD3, T-cell co-receptor. The Phase 1 clinical trials for ABP-102 are led by Celltrion and aim to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with HER2-positive solid tumors (such as breast and gastric cancers). ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting vascular endothelial growth factor, or VEGF, and angiopoietin-2, or ANG-2. We plan to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).

Recent Developments

Following the Nasdaq delisting of our securities from the Nasdaq Capital Market, effective February 23, 2026, our securities are trading on the OTC Pink Limited Market under the ticker symbol “ABPO”. The delisting does not affect the Company’s operations, but may have, among other material adverse effects, an adverse impact on the liquidity and market price of the Common Stock and on the Company’s ability to raise capital, including under the SEPA and on favorable terms, if at all, in the future.

On May 28, 2026, the Company received written notification from the Nasdaq Listing and Hearing Review Council (the “Council”) that the Council had reviewed the decision of the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) and had determined to reaffirm the Panel’s decision that due to the Company not having met the terms of the Panel’s November 10, 2025 decision that the Company demonstrate compliance with the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026, the Company’s securities will be delisted from Nasdaq.

The Company expects that Nasdaq may file a Form 25 with the SEC to delist the securities from Nasdaq and deregister the securities under Section 12(b) of the Securities Exchange Act of 1934, as amended (potentially) in the coming days.

The Company expects its common stock will continue to be eligible for quotation on the OTC Pink Limited Market under its existing symbol, “ABP” and its public warrants under the existing symbol “ABPWW.” The Company can provide no assurances that any broker-dealer will make a market in its common stock or public warrants or that trading levels, liquidity, or quotation prices will be maintained. The Company also cautions its stockholders and public warrant holders that trading on the OTC Pink Limited Market may be subject to limited availability of information, reduced transparency and liquidity and greater volatility.

Results of Operations

Results of Operations for the Three Months Ended June 30, 2026 and 2025

The following is a comparative discussion of our results of operations for the three months ended June 30, 2026 and 2025 (in thousands):

Operating expenses: For the Three Months Ended June 2026 2025 Change%
Research and development $9 $313 $(304) -97%
General and administrative 1,166 1,948 (782) -40%
Total operating expenses 1,175 2,261 (1,086) -48%
Loss from operations (1,175) (2,261) 1,086 48%
Other income (expense), net 235 (723) 958 133%
Net loss $(940) $(2,984) $2,044 68%

Revenue

We did not generate revenue during the three months ended June 30, 2026 and 2025. Our ability to generate product or license revenue in the future will depend almost entirely on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize a drug candidate, or enter into collaborations that provide for license and royalty payments to us.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of salaries, payroll taxes, employee benefits and share-based compensation for those individuals involved in research and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies and clinical materials.

Research and development expenses decreased by $0.3 million for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025, primarily due to the majority of research and development personnel being on furlough since October 2024 and then subsequently terminated in the fourth quarter of 2025. The overall decrease in expenses was a result of the decrease in research and development activities while raising additional capital necessary to resume our research and development programs.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation and benefits to our personnel not involved in research and development efforts, costs related to our directors, and senior advisors; professional service fees, including accounting and legal services and other consulting services.

General and administrative expenses decreased by $0.8 million for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025, primarily due to the decrease of approximately $0.3 million in legal and accounting expenses, approximately $0.2 million in facilities and supplies costs and $0.2 million in share-based compensation expense as a result of the cost reduction efforts implemented in the second half of 2025.

Other Income (Expense), Net

Other income (expense), net improved by $1.0 million for the three months ended June 30, 2026, as compared to the three months ended June 30, 2025. This change is primarily due to the loss of approximately $0.6 million on the change in the fair value of the embedded derivative liabilities and the loss on the settlement of the convertible notes of approximately $0.1 million recognized during the three months ended June 30, 2025, as well as the decrease in interest expense of approximately $0.2 million.

Results of Operations for the Six Months Ended June 30, 2026 and 2025

The following is a comparative discussion of our results of operations for the six months ended June 30, 2026 and 2025 (in thousands):

Operating expenses: For the Six Months Ended June 2026 2025 Change%
Research and development $22 $638 $(616) -97%
General and administrative 2,086 4,581 (2,495) -54%
Total operating expenses 2,108 5,219 (3,111) -60%
Loss from operations (2,108) (5,219) 3,111 60%
Other income (expense), net 140 (1,652) 1,792 108%
Net loss $(1,968) $(6,871) $4,903 71%

Revenue

We did not generate revenue during the six months ended June 30, 2026 and 2025. Our ability to generate product or license revenue in the future will depend almost entirely on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize a drug candidate, or enter into collaborations that provide for license and royalty payments to us.

Operating Expenses

Research and Development Expenses

Research and development expenses decreased by $0.6 million for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025, primarily due to the majority of research and development personnel being on furlough since October 2024 and then subsequently terminated in the fourth quarter of 2025. The overall decrease in expenses was a result of the decrease in research and development activities while raising additional capital necessary to resume our research and development programs.

General and Administrative Expenses

General and administrative expenses decreased by $2.5 million for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025, primarily due to the decrease of approximately $1.2 million in legal and accounting expenses, approximately $0.4 million in facilities and supplies costs, approximately $0.4 million reversal of expenses upon settlement of outstanding liabilities to a former director and $0.5 million in executive and share-based compensation expenses as a result of the cost reduction efforts implemented in the second half of 2025.

Other Income (Expense), Net

Other income (expense), net improved by $1.8 million for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025. This change is primarily related to the interest expense for the one-time charge for the fair value of the warrants issued under the promissory note with an executive in the amount of approximately $0.7 million during the six months ended June 30, 2025, in which there was no similar interest expense activity during the six months ended June 30, 2026. The remaining change is due to the loss of approximately $0.6 million on the change in the fair value of the embedded derivative liabilities during the six months ended June 30, 2025, the decrease in interest expense of approximately $0.2 million, and the loss of approximately $0.2 million for the change in fair value of the SEPA Put Rights asset and the loss on the settlement of the convertible notes of approximately $0.1 million recognized during the six months ended June 30, 2025.

Liquidity, Capital Resources and Going Concern

To date, we have financed our operations primarily through the sale of equity securities and convertible debt, proceeds from the Merger and related PIPE financing, borrowings under loan facilities and, to a lesser extent, through payments received in connection with collaboration and license agreements. Since our inception, we incurred significant recurring losses, including net losses of $2.0 million and $6.9 million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, we had an accumulated deficit of $121.0 million. We expect to incur operating losses in the foreseeable future.

In April 2025, the Company received multiple notices from the Listing Qualifications Department staff of the Nasdaq Stock Market (“Nasdaq”) indicating that it no longer met several continued listing requirements. Specifically, its stock price had remained below Nasdaq’s $1.00 minimum bid price requirement for 30 consecutive business days, and it failed to meet the required minimum levels for both Market Value of Publicly Held Shares (the “MVPHS requirement”) and Market Value of Listed Securities (the “MVLS requirement”). Nasdaq granted compliance periods through September and October 2025 to allow the Company time to regain compliance.

After failing to satisfy the minimum bid price requirement by the September 2025 deadline, the Company requested a hearing before a Nasdaq Hearings Panel (the “Panel”). At an October 2025 hearing, management presented its plan to regain compliance with the minimum bid price, MVPHS, and MVLS requirements. Nasdaq subsequently allowed the Company to remain listed temporarily, subject to strict conditions and deadlines, including demonstrating compliance with Nasdaq’s minimum equity standard by February 16, 2026.

The Company did not meet the required equity standard by the deadline, and on February 18, 2026, the Panel notified the Company that its securities would be delisted. Trading of the Company’s stock on Nasdaq was suspended on February 23, 2026, and the shares began trading on the OTC Pink Limited Market tier under the ticker symbol “ABPO.” Although the Company appealed the delisting decision, on May 28, 2026, the Nasdaq Listing and Hearing Review Council upheld the Panel’s ruling. The Company expects that Nasdaq may file a Form 25 with the SEC to delist the securities from Nasdaq and deregister the securities under Section 12(b) of the Securities Exchange Act of 1934, in the coming days.

The delisting does not affect the Company’s operations, but results in significant material adverse consequences, including the loss of federal preemption of state securities laws (blue sky laws) that will make certain finance and securities transactions more costly and involve increased complexities, along with the costs associated with trading on the Over-the-Counter market, as well as the following:

  • a limited availability of market quotations for our securities;
  • reduced liquidity for our securities;
  • a determination that our Common Stock is “penny stock” which will require brokers trading in the Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;
  • a limited amount of news and analyst coverage; and
  • a decreased ability to issue additional securities or obtain additional financing including under SEPA (see Note 10 of the Notes to the Unaudited Condensed Consolidated Financial Statements) and on favorable terms, if at all, in the future.

In January and February 2026, the Company issued 3,162,785 shares of common stock with the aggregate gross purchase price of approximately $7.3 million under Advance Notices to YA in accordance with the terms of the SEPA.

As of June 30, 2026, the Company had cash of $4.2 million. Due to its current liabilities, the cash available to the Company will not be sufficient to allow the Company to operate for at least 12 months from the date that the unaudited condensed consolidated financial statements are issued. The future viability of the Company is largely dependent on its ability to raise additional capital to finance its operations. The Company expects to seek additional funding through equity and debt financings, collaboration agreements and research grants. If the Company is unable to obtain funding, the Company could be forced to further delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.

Accordingly, based on the considerations discussed above, management has concluded there is substantial doubt as to the Company’s ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued. The Company plans to continue to fundraise, as well as seek alternate revenues from collaboration and license agreements. If adequate funds are not available, the Company may be required to initiate steps to further slow cash burn, extending the cash runway until financing can be secured. The condensed consolidated financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might result from the outcome of this uncertainty.

Future Funding Requirements

We expect our expenses to increase in connection with our ongoing activities, particularly as we advance the pre-clinical activities and clinical trials of our product candidates. The timing and amount of our operating expenditures will depend largely on:

  • the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates;
  • the clinical development plans we establish for our product candidates;
  • the number and characteristics of product candidates and programs that we develop or may in-license;
  • the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;
  • our ability to obtain marketing approval for our product candidates;
  • the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product candidates, including any such patent claims and intellectual property rights that we have licensed pursuant to the terms of a license agreement;
  • our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;
  • the cost and timing of completion of commercial-scale outsourced manufacturing activities with respect to our product candidates;
  • our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;
  • the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own;
  • the success of any other business, product or technology that we acquire or in which we invest;
  • the costs of acquiring, licensing or investing in businesses, product candidates and technologies;
  • our need and ability to hire additional management, and scientific and medical personnel;

29

  • the costs to operate as a public company in the United States, including the need to implement additional financial and reporting systems and other internal systems and infrastructure for our business;
  • the effect of competing technological and market developments; and
  • general economic, industry and market conditions or other events or factors, many of which are beyond our control, such as the impact of any natural disasters, or public health emergencies, and the impacts of inflation, interest rates, actual or anticipated bank failures, actual or anticipated government tariffs, and international military or geopolitical conflicts.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to further delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.

The following table summarizes our cash flows for the six months ended June 30, 2026 and 2025 (in thousands):

For the Six Months Ended June 30, 2026 2025 Change%
Net cash used in operating activities $(3,134) $(2,552) $(582) 23%
Net cash provided by financing activities $7,288 $1,589 $5,699 359%

Net cash used in operating activities for the six months ended June 30, 2026, increased by $0.6 million as compared to the six months ended June 30, 2025. Although the operating expenses, excluding non-cash items, decreased by $2.8 million for the six months ended June 30, 2026 as compared to the six months ended June 30, 2025, the cash used in operating activities increased by $3.4 million due to the timing of disbursements, net of collections on accounts receivable, in the first half of 2026 as compared to the first half of 2025.

Net cash provided by financing activities increased by $5.7 million for the six months ended June 30, 2026 as compared to the six months ended June 30, 2025. The cash provided during the six months ended June 30, 2026 is primarily from the sale of the common stock shares to YA in accordance with the terms of the SEPA for gross cash proceeds of $7.3 million. The cash provided during the six months ended June 30, 2025 is due to proceeds received from issuances of debt of $1.8 million and proceeds of $0.1 million from the settlement of the Forward Purchase Agreement which were partially offset by $0.3 million of payments made on notes payable.

Critical Accounting Policies and Estimates

This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of these unaudited condensed consolidated financial statements, as well as the reported expenses and net loss incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no changes to our critical accounting policies and estimates as compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.

Recent Accounting Pronouncements

See Note 2*, Summary of Significant Accounting Policies* of the Notes to the Unaudited Condensed Consolidated Financial Statements for a discussion of recent accounting pronouncements.

Controls and procedures

As filed, 4,467 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Management, under the supervision and with the participation of the Company’s principal executive and principal financial officer, have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Disclosure controls and procedures are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Based on this evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were not effective as of June 30, 2026 due to the material weaknesses described below.

Remediation Efforts to Address a Previously Identified Material Weakness in Internal Control over Financial Reporting

As described in Item 9.A Controls and Procedures of our 2025 Form 10-K, for the year ended December 31, 2025, management identified material weaknesses in its internal controls, related to the Company having inadequate existing control to ensure timely identification and evaluation of contractual obligations such as license agreements and failing to design and maintain formal written policies and procedures regarding internal controls over financial reporting. As of December 31, 2025, the Company successfully remediated the previous material weakness related to segregation of duties over internal wire transfer authorization and access to bank accounts. The Company is in process of implementing and testing its internal control to address the remaining material weaknesses.

A material weakness is a deficiency, or combination of deficiencies, in a company’s internal control over financial reporting such that there is a reasonable possibility that a material misstatement of its annual or interim financial statements will not be prevented or detected on a timely basis.

The Company will continue to review and improve its internal controls over financial reporting to address the underlying causes of the material weaknesses and control deficiencies. Such material weaknesses and control deficiencies will not be remediated until the Company’s remediation plan has been fully implemented, and it has concluded that its internal controls have been operating effectively for a sufficient period of time.

To address these material weaknesses, management, under the oversight of the audit committee, has devoted, and plans to continue to devote significant effort and resources to the remediation and improvement of its internal control over financial reporting:

  • The Company redesigned and implemented proper authorization procedures and access controls with respect to wire transfers and bank account access.
  • The Company will continue to implement a review process by management and the Board of Directors to ensure timely identification of liabilities related to the contractual obligations and license agreements.
  • The Company continues to develop formalized policies and procedures regarding internal controls over financial reporting.

The material weaknesses will not be remediated until the Company’s remediation plan has been fully implemented, for which the Company would be able to conclude that its internal controls were operating effectively for a sufficient period of time.

We can offer no assurance that these initiatives will ultimately have the intended effects.

Changes in Internal Control over Financial Reporting

Except for the remediation actions described above, there were no changes in our internal control over financial reporting (as defined by Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the most recently completed quarter, that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 11,357 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Factors that could cause our actual results to differ materially from those in this report include the risk factors described in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2025, as may be updated in subsequent periodic reports we file with the SEC. Other than as set forth below, there have been no material changes to the risk factors described in our most recent Form 10-K.

Our failure to meet Nasdaq’s continued listing requirements could result in a further delisting of our shares.

In April 2025, the Company received multiple notices from the Listing Qualifications Department staff of the Nasdaq Stock Market (“Nasdaq”) indicating that it no longer met several continued listing requirements. Specifically, its stock price had remained below Nasdaq’s $1.00 minimum bid price requirement for 30 consecutive business days, and it failed to meet the required minimum levels for both Market Value of Publicly Held Shares (the “MVPHS requirement”) and Market Value of Listed Securities (the “MVLS requirement”). Nasdaq granted compliance periods through September and October 2025 to allow the Company time to regain compliance.

After failing to satisfy the minimum bid price requirement by the September 2025 deadline, the Company requested a hearing before a Nasdaq Hearings Panel (the “Panel”). At an October 2025 hearing, management presented its plan to regain compliance with the minimum bid price, MVPHS, and MVLS requirements. Nasdaq subsequently allowed the Company to remain listed temporarily, subject to strict conditions and deadlines, including demonstrating compliance with Nasdaq’s minimum equity standard by February 16, 2026.

The Company did not meet the required equity standard by the deadline, and on February 18, 2026, the Panel notified the Company that its securities would be delisted. Trading of the Company’s stock on Nasdaq was suspended on February 23, 2026, and the shares began trading on the OTC Pink Limited Market tier under the ticker symbol “ABPO.” Although the Company appealed the delisting decision, on May 28, 2026, the Nasdaq Listing and Hearing Review Council upheld the Panel’s ruling. The Company expects that Nasdaq may file a Form 25 with the SEC to delist the securities from Nasdaq and deregister the securities under Section 12(b) of the Securities Exchange Act of 1934, in the coming days.

The delisting does not affect the Company’s operations, but may have, among other material adverse effects, an adverse impact on the liquidity and market price of the Common Stock and on the Company’s ability to raise capital, including under the SEPA (see Note 10 of the Notes to the Unaudited Condensed Consolidated Financial Statements) and on favorable terms, if at all, in the future.

Following the above-referenced suspension of trading on Nasdaq, the Company expects its common stock will continue to be eligible for quotation on the OTC Pink Limited Market under the ticker symbol “ABPO” and its public warrants under the existing symbol “ABPWW.” The Company can provide no assurances that any broker-dealer will make a market in its common stock or public warrants or that trading levels, liquidity, or quotation prices will be maintained. The Company also cautions its stockholders and public warrant holders that trading on the OTC Pink Limited Market may be subject to limited availability of information, reduced transparency and liquidity and greater volatility.

We can provide no assurance that any action taken by us in the future to restore compliance with listing requirements would allow our shares to become listed again, stabilize the market price or improve the liquidity of our shares or prevent future non-compliance with Nasdaq’s listing requirements.

Following the unsuccessful appeal to Nasdaq we expect to face significant material adverse consequences, including the loss of federal preemption of state securities laws (blue sky laws) that will make certain finance and securities transactions more costly, ineligible and/or involve increased complexities, along with the costs associated with trading on the OTC Market, as well as the following:

  • a limited availability of market quotations for our securities;
  • reduced liquidity for our securities;
  • a determination that our Common Stock is “penny stock” which will require brokers trading in the Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;
  • a limited amount of news and analyst coverage; and
  • a decreased ability to issue additional securities or obtain additional financing in the future.

We will need substantial additional funds to advance development of our product candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future product candidates.

The development of biopharmaceutical product candidates is capital-intensive. If our product candidates enter and advance through pre-clinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing and sales capabilities. We have used substantial funds to develop our technology and product candidates and will require significant additional funds to conduct further research and development and pre-clinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any, that are approved for commercial sale. In addition, we expect to incur additional costs associated with operating as a public company, which will require additional funding to operate in parallel with and in addition to our clinical and development costs of our assets.

Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. The timing and amount of our operating expenditures will depend largely on:

  • the timing and progress of pre-clinical and clinical development activities;
  • the number and scope of pre-clinical and clinical programs we decide to pursue;
  • the progress of the development efforts of parties with whom we have entered into or may in the future enter into, collaboration and research and development agreements;
  • the timing and amount of milestone or royalty payments we may receive under collaboration agreements;
  • our ability to maintain our current licenses and research and development programs and to establish new collaborations;
  • the costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property rights;
  • the cost and timing of regulatory approvals; and
  • our efforts to hire additional personnel, including personnel to support development, marketing and, if successful, commercialization of our product candidates.

If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and pre-clinical studies or clinical trials, if any, limit strategic opportunities or other corporate restructuring activities. We also could be required to seek funds through arrangements with partners or others that may require us to relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and until our product candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through equity and debt financings, payments received under collaboration agreements, and research grants We will be required to seek additional funding in the future and currently intend to do so through additional collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution, and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.

Should we pursue a deregistration or be involuntarily deregistered, resulting in “going dark”, this may limit our ability to raise capital on favorable terms as a private company.

If we are involuntarily deregistered by the SEC or if we complete a voluntary deregistration under the Exchange Act (referred to as “going dark”), we will cease filing public financial reports. Following any such transition to a private non-reporting company, our access to traditional capital markets may be constrained since any future debt or equity financings we pursue will likely rely entirely on private placement markets. Private investors and lenders often demand higher yields, stricter financial covenants, greater board representation, or significant liquidation preferences to compensate for the lack of liquidity and mandatory and more stringent public disclosure requirements. We cannot assure you that private financing will be available when needed, or that the commercial terms will be acceptable to us.

Additionally, any residual OTC trading will feature extremely limited liquidity, wider bid-ask spreads, and heightened price volatility. As a result of the lack of an active public trading market, private financing rounds often suffer from a steep “illiquidity discount.” While the Company believes that its stock price per share has been severely undervalued and, therefore, capital raising terms may ultimately prove more favorable on a private company financing basis, there remains the possibility that financing raised after going dark may result in greater equity dilution for existing stockholders than an equivalent public capital raise, especially if the Company’s common stock were still listed and traded on Nasdaq under ordinary and non-distressed circumstances. Further, such a structural shift may result in increased stockholder skepticism, damage to our reputation among alternative lenders, and potentially trigger costly stockholder litigation regarding the loss of liquidity and perceived reduction in fiduciary transparency. Any ongoing litigation or negative market perception will further depress our corporate valuation and complicate our efforts to finalize essential private financings.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2026-04-01 to 2026-06-30$9.0kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2026-01-01 to 2026-06-30$22.0kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2026-04-01 to 2026-06-30−$1.2mus-gaap:OperatingIncomeLoss
Operating income6 months2026-01-01 to 2026-06-30−$2.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2026-04-01 to 2026-06-30$2.0kus-gaap:InterestExpense
Interest expense6 months2026-01-01 to 2026-06-30$2.0kus-gaap:InterestExpense
Net income3 months2026-04-01 to 2026-06-30−$940.0kus-gaap:ProfitLoss
Net income6 months2026-01-01 to 2026-06-30−$2.0mus-gaap:ProfitLoss
Diluted EPS3 months2026-04-01 to 2026-06-30−$0.16us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2026-01-01 to 2026-06-30−$0.38us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-04-01 to 2026-06-30−$0.16us-gaap:EarningsPerShareBasic
Basic EPS6 months2026-01-01 to 2026-06-30−$0.38us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-04-01 to 2026-06-305,896,048 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2026-01-01 to 2026-06-305,197,159 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2026-01-01 to 2026-06-30−$3.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2026-06-30$4.2mus-gaap:Cash
Current assetsAt period end2026-06-30$5.1mus-gaap:AssetsCurrent
Total assetsAt period end2026-06-30$5.2mus-gaap:Assets
Current liabilitiesAt period end2026-06-30$8.2mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2026-06-30−$3.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-26-090028. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.